Pharmacyclics — Technical Presentation (June 2011)
22 slides from Pharmacyclics's technical presentation, Jun 6, 2011
Slide 1: Activity and tolerability of the Btk inhibitor PCI-32765 in CLL/SLL
Activity and tolerability of the Bruton's tyrosine kinase (Btk) inhibitor PCI-32765 in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Interim results of a phase IB/II_ study. JouN C. ByrD, MD}, KristieE A. Blum, MD+, Jan A. BurGeR, MID2, PHD, STEVEN E. CoutrE, MD?,
Slide 2: Disclosures
Disclosures John Byrd, MD RESEARCH FUNDING/PI: Pharmacyclics (clinical trial work) EMPLOYEE: N/A STOCKHOLDER: N/A CONSULTANT: Pharmacyclics (unpaid) SCIENTIFIC ADVISORY BOARD: Pharmacyclics (unpaid)
Slide 3: Bruton's Tyrosine Kinase (Btk)
Bruton’s Tyrosine Kinase (Btk) ACritical B-Cell Signaling Kinase B cell receptor B-cell antigen receptor (BCR) signaling is required for tumor expansion and proliferation Bruton’s Tyrosine Kinase (Btk) is an essential element of the BCR signaling pathway Mutations in Btk prevent B cell maturation In
Slide 4: PCI-32765: Novel Small Molecule Inhibitor of BTK
PCI-32765: Novel Small Molecule Inhibitor of BTK * Forms a specific and irreversible bond with cysteine-481 in Btk 9 AY * Potent Btk inhibition at ICcog = 0.5 nM * Orally bioavailable with daily dosing resulting in 24-hr target inhibition + — Inhibits BCR signaling and active in ES spontaneous canin
Slide 5: Study Design: PCYC 1102
Study Design: PCYC 1102 * Single-agent, multi-cohort study of PCI-32765 in two subject populations with symptomatic CLL/SLL — Treatment-Naive, aged 2 65 years * Dose (May 2010 - March 2011): 420 mg/day until progression — Relapsed/Refractory (RR) * Dose #1 (May — September 2010): 420 mg/day until pr
Slide 6: Interim Analysis of an Ongoing Trial
Interim Analysis of an Ongoing Trial * Based on data entered into the Pharmacyclics study database by investigators as of May 9, 2011 * Safety population: — Subjects initiating treatment prior to March 7: n=83 * Due to differential follow-up time?, subjects treated in the 840 mg/d cohort are evaluab
Slide 7: Subject Eligibility
Subject Eligibility Diagnosis of CLL or SLL and requirement for treatment per NCI or IWG guidelines For relapsed/refractory cohorts: 22 prior therapies including a purine analog Adequate end-organ function ANC2 0.75 x 109/L” Platelets > 50 x 10°/L” ALT s 2.5 x ULN Creatinine < 1.5 x ULN No active/un
Slide 8: Subject Characteristics
Subject Characteristics Treatment-Naive | Relapsed/Refractory | Relapsed/Refractory 420 mg/d (N=23) | _420mg/d (N=27) 840 mg/d (N=33) Age, y Median: 71 64 65 Range: 66-84 40-81 44-80 Dx, # pts CLL: 22 (96%) 26 (96%) 32 (97%) SLL: 1 (4%) 1(4%) 1 (3%) Prior Rx, # Median: CY) 3 5 Range: 2-10 2-12 Prior
Slide 9: Subject Characteristics (cont.)
Subject Characteristics (cont.) Treatment- Relapsed/ Relapsed/ Naive Refractory Refractory 420 mg/d 420 mg/d 840 mg/d (N=23) (N=27) (N=33) Cytopenia at baseline, % ANC < 1500/UL 1 (4%) 6 (22%) 17 (52%) HGB < 11g/dL 7 (30%) 4 (15%) 19 (58%) Platelets < 100,000/uL 9 (39%) 8 (30%) 22 (67%) Prognostic M
Slide 10: Subject Disposition
Subject Disposition Treatment- Relapsed/ Naive Refractory 420 mg/d 420 mg/d (N=23) (N=27) Number of subjects 23 27 Follow-up Median (months) 63 78 Range 1.4-9.2 07-95 Subjects still on study 21 (91%) 22 (81%) Subject Discontinued 2 (9%) 5 (19%) Primary Reasons for Discontinuation Disease Progression
Slide 11: Overview of Safety
Overview of Safety Treatment- Relapsed/ Relapsed/ Naive Refractory Refractory 420mg/d 840 mg/d (n=27) (n=33) Deathon study, # (%)* 4 0 (0%) 2(6%) Subject with AE leading to 1(4%) 1(4%) 1 (3%) discontinuation, # (%) Subjects with SAE, # (%) 4 (17%) 11 (41%) 15 (46%) ~-Related SAE, # (%) 0 (0%) 5 (19%
Slide 12: Grade 3/4 Hematology Toxicity
Grade 3/4 Hematology Toxicity Treatment- Relapsed/ Relapsed/ AG Naive Refractory Refractory 1 Grade 3/4 Hematology toxicity’ 420me/d 420me/d 840me/d (n=23) (n=27) (n=33) Grade3 Grade4 Grade3 Grade4 Grade3 Grade4 Neutropenia 0% 0% 4% 0% 9% 9% Anemia 4% 0% 7% 0% 9% 3% Thrombocytopenia 0% 4% 0% 4% 9% 0
Slide 13: Common AEs (All Grades)
Common AEs (All Grades) Treatment-Naive 420 mg/d (n=23) Diarrhea (T) 48% Nausea INN 39% Vomiting [NNN 17% Dyspepsia NINN 22% Contusion [4% Muscle spasms 17% Rash MEN! 26% uri Mi 13% Fatigue MEN 17% 0% 20% 40% 60% 80% Relapsed/Refractory 420 mg/d (n=27) ET 70%, ME 23° ME | 22%, ls 10% EE 33° EL 2, im
Slide 14: Pattern of Response: Blood Lymphocytes vs Lymph Nodes
Pattern of Response: Blood Lymphocytes vs Lymph Nodes Treatment-Naive Patients 50 100 150 200 250 200 8 0 100 150 200 250 300 200. 400. 600 ALC 10%7L % of Base SPD Time (Days) Time (Days) Relapsed/Refractory Patients 200 400 % of Base SPD 0 50 100 150 200 250 300 50 100 150 20 Time (Days) Time (Days
Slide 15: Response Criteria
Response Criteria * NHLIWG criteria! were applied to SLL cases without modification. * The 2008 CLLIWG criteria? were applied to CLL cases with the following modifications: An isolated lymphocytosis, in the absence of other parameters meeting the criteria for PD, was not considered PD. Subjects expe
Slide 16: Best Response
Best Response Treatment- ive Relapsed/ Refractory 420 mg/d 420mg/d N 21 27 cR 1(5%) 1 (4%) 13 (62%) 12 (44%) | 67% ili ] 4 (19%) | “11. (41%) sD 2 (10%) 1(4%) PD 0 1 (4%) NE 1(5%) 1(4%)
Slide 17: Response Rate %
Response Rate % Initial (Cycle 2) Response Assessment and 80% 60% 40% 20% 0% Best Response (420 mg/d Cohorts) Treatment-Naive (420 mg/d) 33% 24% Cycle 2 (n=21) Relapsed/Refractory (420 mg/d) 80% 67% 60% 59% 48% So, 40% pa il “tf ; 0% L Best Response Cycle 2 Best Response (n=21) (n=27) (n=27) | CR BP
Slide 18: Initial (Cycle 2) Response Assessment by Dose
Initial (Cycle 2) Response Assessment by Dose: Relapsed/Refractory 420 mg/d 840 mg/d . 70% aK 60% 59% se 50% 2 E 40% a 5 30% $ a 19% | «© 20% 15% | . = (las 0% Cycle 2 (n=27) Cycle 2 (n=33) | CR & PR & NodalResponse
Slide 19: Best Response by Risk Features
Best Response by Risk Features Relapsed/Refractory Patients: 420 mg/d Cohort Molecular Risk Feature 1WG Response Nodal Response 48% 41% Overall Del17p 9 4/9 (44%) 3/9 (33%) Del11q 8 5/8 (63%) 3/8 (38%) IgVH unmutated 17 9/17 (53%) 5/17 (29%)
Slide 20: Improvement in Hematologic Parameters
Improvement in Hematologic Parameters Platelets over time Hemoglobin over time in subjects with plt <50x109/L in subjects with Hgb <9g/dL at study entry at study entry (n=12) (n=8) g =| 2 ~ Za g i 3” ri Voz ry 2 | zg Y Bal / 2\, A We 11526 43 56 88 112 140 16s 196 228 252 © «115284356 84 112 140 60
Slide 21: Time on Study
Treatment-Nalve Relapsed/Refractory (420 me/d) (420 mg/d) Time on Study @ sae ™@ WC oF|PI Decision Time (months) 15
Slide 22: Conclusions
Conclusions |-32765 is modest, ge! ing extended continuous dosing in CLL — The majority of adverse events are grade 1 or 2 in severity — Cytopenias were relatively uncommon in patients treated at 420 mg/day * Grade 3/4 neutropenia was more common in the 840 mg group * The interim Phase II data confi